Stallergenes S.A. to merge with Greer Laboratories

The Board of Directors of Stallergenes S.A. has reviewed a project submitted by its majority shareholder, Ares Life Sciences, to combine the activities of Stallergenes and the US company, Greer Laboratories Inc., to create the worldwide leader in allergy immunotherapy. Ares Life Sciences currently owns 100% of Greer and 77.3% of Stallergenes. Under the transaction proposed by Ares Life Sciences, the businesses of Stallergenes and Greer would be combined under the common ownership of Ares Allergy Holding PLC, the English subsidiary of Ares Life Sciences. Shares of Ares Allergy Holding PLC would be listed on EURONEXT Paris. Founded in 1904 and based in North Carolina (USA), Greer is the leader in allergy immunotherapy in the US with a market share of approximately 52% and is Stallergenes' partner for the marketing and distribution of Oralair in the US.